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Antagonist resistanceR5 HIV-1 strains resistant to the CCR5 antagonist Maraviroc (MVC) can use drug-bound CCR5. We
demonstrate that MVC-resistant HIV-1 exhibits delayed kinetics of coreceptor engagement and fusion during
drug-bound versus free CCR5 infection of cell lines. Antibodies directed against the second extracellular loop
(ECL2) of CCR5 had greater antiviral activity against MVC-bound compared to MVC-free CCR5 infection.
However, in PBMCs, only ECL2 CCR5 antibodies HGS004 and HGS101, but not 2D7, inhibited infection by MVC
resistant HIV-1 more potently with MVC-bound than with free CCR5. In addition, HGS004 and HGS101, but
not 2D7, restored the antiviral activity of MVC against resistant virus in PBMCs. In ﬂow cytometric studies,
CCR5 binding by the HGS mAbs, but not by 2D7, was increased when PBMCs were treated with MVC,
suggesting MVC increases exposure of the relevant epitope. Thus, HGS004 and HGS101 have antiviral
mechanisms distinct from 2D7 and could help overcome MVC resistance.725 W. Lombard St., Rm N549,
redia).
l rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
The identiﬁcation of CCR5 as an HIV-1 coreceptor (Alkhatib et al.,
1996; Choe et al., 1996; Deng et al., 1996; Dragic et al., 1996),
prompted by the discovery of CCR5 ligand β-chemokines with
antiviral activity (Cocchi et al., 1995), led to the development of
antiretroviral CCR5 inhibitors, including small molecules and anti-
bodies. In clinical trials of HIV-1 patients infected with CCR5-tropic
HIV-1 only (R5 strains), these agents have achieved potent viral
suppression (Currier et al., 2008; Gulick et al., 2008, 2007; Landovitz
et al., 2008; Suleiman et al., 2010; Wilkin et al., 2010; Yeni et al.,
2009). At present, the small-molecule CCR5 antagonist Maraviroc
(MVC) is the only licensed CCR5 inhibitor (2007; 2009). The CCR5
antibodies PRO 140 and HGS004 have signiﬁcantly reduced HIV-1
RNA in clinical trials of patients infected with R5 HIV-1 only (Jacobson
et al., 2010a, 2008, 2010b; Lalezari et al., 2008). However, viral
resistance to CCR5 inhibitors has been demonstrated (Cooper et al.,
2010; Demarest et al., 2009; Gulick et al., 2008, 2007; Marozsan et al.,
2005; Westby et al., 2007).
Resistance to CCR5 inhibitors could arise from a switch to use of
the alternative coreceptor CXCR4, either by acquiringmutations in the
viral envelope (Env) protein or by selection of preexisting CXCR4-using variants (X4 HIV-1). However, in vitro data indicate that a
switch to CXCR4 usage under CCR5 inhibitor pressure is quite rare
(McNicholas et al., 2010). In vivo, some patients failing treatment with
MVC or other antagonists harbored X4 variants, but DNA sequencing
demonstrated that such variants were selected from minor popula-
tions already present prior to treatment (Kitrinos et al., 2009; Tsibris
et al., 2009, 2008; Westby et al., 2006). Resistance could also arise
from the emergence of mutations that result in increased afﬁnity for
CCR5 (Pugach et al., 2007; Trkola et al., 2002; Tsibris et al., 2008;
Westby et al., 2007). In genotypic assays, resistance is associated with
mutations in Env, generally in the V3 region of gp120 (Kuhmann et al.,
2004; Marozsan et al., 2005; Ogert et al., 2008; Tsibris et al., 2008), but
no such signature mutations have been identiﬁed to date. Resistance
is commonly determined using the Phenosense Entry Susceptibility
Assay (Monogram Biosciences, San Francisco, CA), a single-cycle, Env-
pseudotype assay based on U87 cells expressing high levels of CD4
and CCR5/CXCR4. In this assay, resistance is manifested by decreases
in maximum percentage of inhibition (MPI) at saturating concentra-
tions of antagonist (Pugach et al., 2007; Westby et al., 2007). The MPI
level reﬂects the efﬁciency with which the virus uses the antagonist-
free versus antagonist-bound forms of CCR5, with the MPI decreasing
as the efﬁciency with antagonist-bound CCR5 increases. We (Heredia
et al., 2008) and others (Pugach et al., 2009) have previously shown
that CCR5 density on target cells modulates MPI values.
We now demonstrate that infection of cell lines with an HIV-1
reporter virus bearing the envelope (Env) of a MVC-resistant HIV-1
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lower viral afﬁnity forMVC-bound than forMVC-free CCR5.We further
show that CCR5mAbs HGS004 and HGS101, but not other CCR5mAbs,
restored MVC inhibition of MVC-resistant HIV-1 infection of PBMCs.
We conclude that CCR5 mAbs HGS004 and HGS101 preferentially
inhibit MVC-resistant virus infection via antagonist-bound CCR5 and
restore sensitivity of resistant virus to MVC, suggesting a potentially
effective approach to control resistance to MVC.Results
MVCres HIV-1 infection in the presence of MVC is inefﬁcient at low
CCR5 density
We evaluated MVC inhibition of reporter viruses pseudotyped
with Env of MVCsens- and MVCres HIV-1 CC1/85 in a panel of JC
clones expressing constant CD4 density (~105 molecules/cell), but
differing CCR5 densities (Fig. 1). The panel includes clones expressing
levels of CCR5 similar to those in primary CD4+ T cells, typically
ranging from ~2×103 to ~15×103 CCR5 molecules/CD4+ T cell
(Hladik et al., 2005; Lee et al., 1999b; Reynes et al., 2000). MVCres
HIV-1 CC1/85 uses both MVC-bound CCR5 and free CCR5 as
coreceptor (Westby et al., 2007). As expected, MVC fully inhibited
MVCsens but not MVCres pseudovirus infection, with resistance
manifested by plateaus in maximum percentage of inhibition (MPI) of
less than 100% (Pugach et al., 2007; Westby et al., 2007). However,
MPI levels increased at reduced CCR5 densities. MPI levels in JC53
(130×103 CCR5/cell), JC6 (27×103 CCR5/cell), and JC57 (9×103
CCR5/cell) were 60, 90, and 95%, respectively. In JC10 (2×103 CCR5/
cell) and JC20 (0.7×103 CCR5/cell), MVCres HIV-1 Env pseudovirus
was fully inhibited in the presence of high MVC concentrations. TheseFig. 1. MVCres HIV-1 infection in the presence of MVC is inefﬁcient at low CCR5 density. H
(b) were used to infect JC clones with same CD4 but different CCR5 densities, in the presenc
luciferase activity in cell lysates on day 3 after infection. In control experiments using unin
luciferase activities ranged between 20 and 40 RLU (not shown). Right panels: Infectivity data
and percentages of MVC inhibition determined (right panels). Data points are mean±S.D. oresults demonstrate a lower efﬁciency of MVCres HIV-1 Env
pseudovirus using MVC-bound CCR5 compared to MVC-free CCR5.MVCres HIV-1 infection of cell lines via MVC-bound CCR5 is more
sensitive to CCR5 mAb 2D7 than infection via free CCR5
Less efﬁcient use of MVC-bound CCR5 by MVCres HIV-1 could be
due to a lower gp120 afﬁnity for bound compared to free CCR5. To test
this, we evaluated CCR5 mAb 2D7 inhibition of MVCsens and MVCres
HIV-1 infection of JC6 cells in the presence and absence of 10 μMMVC,
a saturating drug concentration. 2D7 competes with HIV-1 gp120 for
binding to the ECL2 of CCR5 and has similar afﬁnities forMVC-free and
MVC-bound CCR5 (Ji et al., 2007b;Maeda et al., 2008;Wu et al., 1997).
In the absence of MVC, 2D7 inhibited MVCsens- and MVCres HIV-1
Env pseudotypes with EC50 values of 0.77 and 0.25 μg/ml, respectively
(Fig. 2a). In the presence of MVC, MVCsens Env pseudotype was
completely inhibited and inhibition was not affected by addition of
2D7, whereas MVCres Env pseudotype became considerably more
sensitive to 2D7 (2D7 EC50=0.03 μg/ml) when MVC was added. The
order of addition of 2D7 and MVC had no effect on antiviral activity
(not shown). In a control experiment using mAb 45523, which binds
to a multidomain epitope of CCR5 and competes with MVC (Ji et al.,
2007b; Maeda et al., 2004), MVCres HIV-1 Env pseudovirus infection
was inhibited (albeit modestly) in the absence, but not in the
presence, of MVC (Fig. 2b). We conﬁrmed the 2D7 inhibition results
using CCR5 mAb ROAb14, which recognizes a region overlapping the
2D7 epitope and, as with 2D7, is unaffected by MVC (Ji et al., 2007b).
Similarly to 2D7, ROAb14 inhibited MVCres HIV-1 more potently in
the presence of MVC. The ROAb14 EC50 values were 0.08 μg/ml for
MVCsens-, 0.02 μg/ml for MVCres-, and only 0.003 μg/ml for MVCres
HIV-1 in the presence of MVC (Fig. 2c). Thus, MVCres HIV-1 infectionIV-1 reporter virus pseudotyped with the Env of MVCsens HIV-1 (a) or MVCres HIV-1
e of varying MVC concentrations. Left panels: Infectivity was determined by measuring
fected cells or infected cells treated with 10 μM T-20 (a fully inhibitory concentration)
in each cell clone were normalized to infectivity values obtained in the absence of drug
f at least 2 replicates and are from one representative experiment of three.
Fig. 2. CCR5mAb2D7 inhibits MVCres HIV-1 infection of JC6 cells more potently in the presence than in the absence ofMVC. JC6 cells were incubated with andwithout 10 μMMVC for
1 h, followed by incubation with serial dilutions of CCR5 antibodies 2D7 (a), 45523 (b) or ROAb14 (c) for an additional hour, and then infected with HIV-1 pseudovirus bearing the
indicated Env. Infectivity was determined bymeasuring luciferase activity on day 3, and data normalized to infectivity in the absence of mAb. Data points are mean±S.D. of at least 2
replicates and are from one representative experiment of four (2D7), two (45523) and three (ROAb14).
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CCR5 mAb inhibition than is infection through MVC-free CCR5.MVCres HIV-1 infection via MVC-bound CCR5 exhibits delayed kinetics
of coreceptor engagement and fusion
Because the binding efﬁciency of HIV-1 Env to CCR5 impacts entry
kinetics and sensitivity to the fusion inhibitor T20 (Platt et al., 2005;
Reeves et al., 2002), we evaluated the kinetics of CCR5 engagement
and fusion during pseudovirus infection of JC6 in the presence and
absence of 10 μM MVC. This was accomplished using time-of-
inhibitor-addition experiments, in which fully inhibitory concentra-
tions of 2D7 or T20 were added at intervals following a synchronized
infection (Fig. 3a). The time required for 2D7 half maximal inhibition
(t½) of MVCsens- andMVCres- HIV-1 entry in the absence of MVCwas
19 and 22 min, respectively. In contrast, under MVC-bound CCR5
conditions, MVCres HIV-1 remained sensitive to 2D7 for a longer time,
with a 2D7 t½ of 41 min. The T20 t½ values of MVCsens and MVCres
without MVC were 29 and 38 min, respectively. MVCres HIV-1 had an
increased T20 t½ of 59 min for MVC-bound CCR5 infection. Together,
the slower kinetics of MVCres HIV-1 engagement of MVC-bound CCR5
compared to that of MVC-free CCR5 is consistent with its higher
sensitivity to 2D7 in the presence of MVC (Fig. 2a), suggesting that a
slower engagement of MVC-bound CCR5 prolongs the opportunity
window for T20 inhibition. We conﬁrmed that MVCres HIV-1
infection via MVC-bound CCR5 is more sensitive to T20 by
determining T20 EC50s in the presence and absence of 10 μM MVC
(Fig. 3b). In the absence of MVC, T20 EC50s for MVCsens and MVCres
HIV-1 were 0.17 and 0.15 nM, respectively. In the presence of MVC,
however, T20 inhibition of MVCres HIV-1 was considerably more
potent (EC50=0.006 nM). To determine whether the kinetics of viral
entry was impacted by different efﬁciencies of CD4 binding, we
evaluated sensitivity to a CD4 mAb, Q4120, which recognizes the N-
terminal region of CD4 and blocks gp120 binding (Healey et al., 1990).
Both MVCsens and MVCres HIV-1 Env pseudovirus were similarlysensitive to Q4120, with EC50s of 0.17 and 0.09 μg/ml, respectively,
suggesting similar efﬁciencies in CD4 binding (Fig. 3c).
CCR5 mAbs HGS004 and HGS101, but not 2D7 or ROAb14, preferentially
inhibit MVC-bound CCR5 infection of MVCres HIV-1 in PBMCs
Enhanced inhibition of MVCres HIV-1 infection in the presence of
MVC by mAbs targeting CCR5 ECL2, such as 2D7 and ROAb14,
suggested a potential approach to control resistance to MVC. We
evaluated and compared the antiviral activities of the CCR5 ECL2
mAbs 2D7, ROAb14, HGS004 and HGS101 (a second-generation
derivative of HGS004 with improved antiviral activity (Lalezari et
al., 2008)) against MVCres HIV-1 in cell lines and PBMCs. In JC6 cells,
similarly to 2D7 and ROAb14, HGS004 and HGS101 inhibited MVCres
HIV-1 Env pseudovirus infection more potently under MVC-bound
CCR5 conditions. Moreover, the antiviral effect was not affected by the
order of addition of mAb and MVC, as expected from their
independent antiviral mechanisms (Fig. 4). HGS004 EC50s were
0.03 μg/ml for MVCsens, 0.05 μg/ml for MVCres, and 0.0001 μg/ml
for MVCres HIV-1 in the presence of MVC. HGS101 gave a similar
pattern of inhibition, with EC50s of 0.001 μg/ml for MVCsens,
0.0003 μg/ml for MVCres, and 0.00002 μg/ml for MVCres HIV-1 in
the presence of MVC.
Similar to results with JC6, both 2D7 and ROAb14 inhibited
replication-competent MVCsens HIV-1 in PBMCs (EC50s of 1.53 and
0.47 μg/ml for 2D7 and ROAb14, respectively) (Fig. 5). The addition of
10 μM MVC fully inhibited MVCsens HIV-1 with and without mAb
(not shown). However, the increased sensitivity of MVCres HIV-1 to
2D7 and ROAb14 antibodies in MVC-treated JC6 cells was not
manifested in PBMCs. In PBMCs, 2D7 and ROAb14 inhibited MVCres
HV-1 similarly in the absence and presence of 10 μM MVC (2D7 EC50
of 1.29 versus 1.0 μg/ml in MVC treatment; ROAb14 EC50 of 0.17
versus 0.16 μg/ml inMVC treatment) (Figs. 5a and b). This was in clear
contrast to CCR5 mAbs HGS004 and HGS101. In PBMCs, HGS004 EC50
values were 0.25 μg/ml for MVCsens HIV-1, 0.24 μg/ml for MVCres
HIV-1 without MVC and 0.06 μg/ml for MVCres HIV-1 with MVC,
Fig. 3. MVCres HIV-1 infection of JC6 cells in the presence of MVC exhibits delayed
kinetics of coreceptor engagement and fusion. (a) Kinetic analysis of CCR5 engagement
(upper panel) and fusion (lower panel) of pseudovirus bearing MVCsen and MVCres
HIV-1 Env during infection of JC6 cells (with and without 10 μM MVC pretreatment).
Pseudovirus particles were spinoculated onto cells at 4 °C, cells washed and transferred
to 37 °C (time 0). At the indicated time points, inhibitors (50 μg/ml 2D7 or 10 μM T20)
were added. Luciferase activity was measured on day 3 and data normalized to activity
obtained at 120 min. (b and c) Sensitivity of pseudovirus bearing MVCsen and MVCres
HIV-1 Env to T20 (b) and CD4 mAb Q4120 (c) during infection of JC6 cells. T20 was
added immediately after virus spinoculation, whereas Q4120 was added 1 h before
spinoculation. Data (means±S.D.) are from 3 independent experiments for (a), and
from 2 experiments for each (b) and (c).
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even greater increases in antiviral potency were observed at EC90
concentrations (HGS004 EC90s of 3 μg/ml for MVCsens, 3 μg/ml for
MVCres, and only 0.3 μg/ml for MVCres HIV-1 in the presence ofMVC). For HGS101, EC50s were 0.03 for MVCsens, 0.03 μg/ml for
MVCres, and 0.01 μg/ml for MVCres HIV-1 in the presence of MVC
(Fig. 5d). Again, increased potency was observed at EC90 concentra-
tions, with HGS101 EC90s of 0.4 μg/ml for MVCsens, 0.4 μg/ml for
MVCres, and only 0.03 for MVCres HIV-1 in the presence of MVC.
These data demonstrate that CCR5 mAbs HGS004 and HGS101, unlike
2D7 and ROAb14, have increased potency against MVCres HIV-1
infection via MVC-bound CCR5 with primary cells.
CCR5 mAbs HGS004 and HGS101, but not 2D7 or ROAb14, restore MVC
inhibition of MVCres HIV-1 in PBMCs
In a complementary approach, we tested each mAb at a
concentration approximating its EC50 in combination with serial
dilutions of MVC (Fig. 6). As expected, MVC fully inhibited MVCsens
HIV-1 (MVC EC50=0.12 nM; 95% CI: 0.06–0.25). However, the MVC
EC50 decreased to 0.02 nM (95% CI: 0.01–0.03) with HGS004 and to
0.007 nM (95% CI: 0.004–0.012) with HGS101, but not with 2D7 (MVC
EC50=0.14 nM; 95% CI: 0.10–0.20) (Fig. 6a). MVCres HIV-1 was not
inhibited by MVC and gave a ﬂat inhibition curve (Fig. 6b), as
previously reported for antagonist-resistant HIV-1 infection of PBMCs
(Pugach et al., 2007;Westby et al., 2007). 2D7 activity against MVCres
HIV-1, normalized to 2D7 inhibition in the absence of MVC, was not
affected by MVC. In contrast, MVC regained antiviral activity against
MVCres HIV-1 when combined with HGS004 (MVC EC50=0.01 nM;
95% CI: 0.005–0.024) or with HGS101 (potent viral inhibition at low
MVC concentrations precluded MVC EC50 determinations) (Fig. 6b).
Antibody ROAb14 gave similar results to those with 2D7 (Supple-
mentary data, Fig. S1). Thus, the combinations of MVC and HGS004/
HGS101 differ from those of MVC and 2D7/ROAb14 in that only the
former restored MVC activity against MVCres HIV-1. Because the
evaluated mAbs can interfere with the binding of β-chemokines to
CCR5 (Ji et al., 2007a,b; Lalezari et al., 2008; Olson et al., 1999; Wu et
al., 1997), we compared the antiviral activities of 2D7 andMVC versus
HGS004 and MVC in CD8-depleted PBMCs (Fig. S2). Results were
similar to those with total PBMCs (Fig. 6), suggesting that β-
chemokines do not account for the observed antiviral differences
between combinations of mAbs and MVC.
Binding of HGS004 and HGS101, but not 2D7, to CCR5 is higher in the
presence than in the absence of MVC in primary cells
The different patterns of viral inhibition between 2D7 (and
ROAb14) and the HGS mAbs could reﬂect differences in binding to
free and MVC-bound CCR5. We evaluated mAb binding, with and
without MVC, in PBMCs stimulated with IL-2 for 10 days, culture
conditions that upregulate CCR5 expression (Bleul et al., 1997). At
saturating concentrations (10 μg/106 cells as determined in opti-
mization experiments), both 2D7 and the HGS mAbs stained similar
percentages of CCR5+ CD4+ T cells (Fig. 7, upper panels).
However, the MFI with 2D7 did not change in the presence of
MVC, whereas those with HGS004 and HGS101 were higher in the
presence of MVC, suggesting that the latter mAbs recognize a
greater proportion of surface CCR5 when CCR5 is bound to MVC
(Fig. 7, lower panels).
Discussion
MVC resistant variants often emerge during treatment with CCR5
antagonists (Cooper et al., 2010; Gulick et al., 2008, 2007). Generally,
resistant variants remain CCR5 tropic but use both antagonist-free and
antagonist-bound CCR5 (Pugach et al., 2007; Westby et al., 2007). In
CCR5-expressing cell lines, resistance is manifested by incomplete
dose response curves with MPI levels that reﬂect the relative
efﬁciency with which the virus utilizes antagonist-bound versus
antagonist-free CCR5 (Pugach et al., 2007;Westby et al., 2007). In this
Fig. 4. Inhibition of MVCres HIV-1 infection of JC6 cells by CCR5 mAbs HGS004 and HGS101. JC6 cells were treated with varying concentrations of antibodies HGS004 (a) or HGS101
(b) for 1 h under the following conditions: mAb alone, mAb added after 1 h preincubation with 10 μMMVC, or mAb added before incubating cells with 10 μMMVC for 1 h. Cells were
then infected with pseudovirus bearing the indicated Env. Luciferase activity was measured on day 3. For each treatment, data were normalized to luciferase signal in the absence of
mAb. Data points are mean±S.D. of at least 2 replicates and are from one representative experiment of two.
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MVCres HIV-1 are inhibited by MVC at low CCR5 densities, suggesting
a reduced viral afﬁnity for MVC-bound CCR5. Antibody 2D7, which
targets CCR5 ECL2 and inhibits gp120 binding, had higher activity
against infection of cell lines by MVCres HIV-1 via MVC-bound CCR5
compared to that using free CCR5. Consistent with these results, the
kinetics of CCR5 engagement and viral fusion were clearly slower for
infection mediated by MVC-bound CCR5. We conﬁrmed the 2D7
results with CCR5 mAb ROAb14, whose epitope overlaps that of 2D7
andwhich also blocks gp120 binding (Ji et al., 2007b). Similar patterns
of inhibition were also observed with mAb HGS004 and its HGS101
derivative.
In contrast, in primary PBMCs, HGS004 and HGS101 but not 2D7 or
ROAb14, inhibited MVCres HIV-1 with greater potency (~10-fold
reduction in EC90s) in MVC-bound than in free CCR5 infection (Fig. 5).Fig. 5. CCR5 mAbs HGS004 and HGS101, but not 2D7 or ROAb14, preferentially inhibit MVC-
with a without 10 μMMVC for 1 h, followed by incubation with varying dilutions of 2D7 (a),
replication-competent, chimeric NL4-3 viruses carrying MVCsens or MVCres HIV-1 Env for 3
concentrations as before. Data are p24 levels on day 7, normalized to p24 levels in the absenc
from 2 different donors and are representative of 4 experiments. Data in b are single data pIn combination with HGS004 or HGS101, MVC became active against
resistant HIV-1 and inhibited sensitive HIV-1 more potently (Fig. 6).
These dissimilarities in antiviral activity between 2D7 and ROAb14
versus HGS004 and HGS101 in diverse cell types support the notion of
CCR5 having multiple forms (e.g., conformation, covalent modiﬁca-
tions, and sulfation differences), varying among cell types and with
different afﬁnity for antagonist and potential to support viral entry in
the free and bound forms (Anastassopoulou et al., 2009; Hill et al.,
1998; Lee et al., 1999a; Olson et al., 1999). Our data suggest that
HGS004 and HGS101 interfere with the ability of CCR5 in either free or
antagonist-bound conformations to serve as coreceptors for MVC
resistant HIV-1 in both primary cells and cell lines.
The binding sites of all four mAbs map to the ECL2 of CCR5. 2D7
and ROAb14 have overlapping epitopes (Zhang et al., 2007), which
differ from those of HGS004 and HGS101 (Lalezari et al., 2008) (Thibound CCR5 infection of MVCres HIV-1 in PBMCs. PHA activated PBMCs were incubated
ROAb14 (b), HGS004 (c) or HGS101 (d) for an additional hour. Cells were infected with
h at aMOI of 0.001. Infected cells were cultured in the presence of inhibitors at the same
e of mAb. In a, c and d, data are means±S.D. of 2 independent experiments using PBMCs
oints from one experiment representative of 3, each with a different donor.
Fig. 6. CCR5 mAbs HGS004 and HGS101, but not 2D7, sensitize MVCres HIV-1 to MVC in PBMCs. PHA-activated PBMCs were incubated with 10-fold serial dilutions of MVC for 1 h,
followed by incubation with the indicated concentration of each CCR5 mAb for an additional hour. Cells were infected with replication-competent MVCsens or MVCres HIV-1 for 3 h
at a MOI of 0.001. Infected cells were cultured in the presence of inhibitors at the same concentrations as before. Data are p24 levels on day 7, normalized to p24 levels in the absence
of MVC. Experimental p24 levels (ng/ml) in the absence of MVC were as follows: 273±38 (no Ab), 142±21 (2D7), 103±11 (HGS004), and 173±14 (HGS101) for MVCsens HIV-1;
180±26 (no Ab), 114±18 (2D7), 113±11 (HGS004), and 103±8 (HGS101) for MVCres HIV-1. Data (means±S.D.) are from one representative experiment of 2, with a different
donor in each experiment.
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resistant HIV-1 with similar potencies in the presence and absence of
MVC in PBMCs probably reﬂects comparable afﬁnities of MVCres HIV-
1 Env for free and antagonist bound CCR5 in these cells, as manifested
by ﬂat inhibition curves (Fig. 6b) (Pugach et al., 2007; Westby et al.,
2007). A greater inhibition of MVC-bound than of free CCR5 infection
in PBMCs by HGS004/HGS101 suggests that their epitopes remain
somewhat exposed on MVC-bound CCR5. Consistent with this, both
HGS mAbs, but not 2D7, gave higher mean ﬂuorescence intensities
(MFI) with MVC-bound CCR5 versus free CCR5 on CD4+ T cells.
Although we have not yet determined antibody afﬁnities or off-rates,
the data suggest that the HGS mAbs recognize a greater proportion ofFig. 7. Flow cytometry analysis of 2D7, HGS004 and HGS101 binding to MVC-bound and fre
without 10 μMMVC, incubated with 10 μg of unconjugated CCR5 antibody or isotype, and st
identiﬁed using ﬂuorochrome-labeled antibodies for detection of CD3, CD4 and CD8. CCR5
positive cells (upper panels) or Mean Fluorescence Intensities (MFI) of the CCR5+ gated poCCR5 molecules when these are occupied by MVC than does 2D7. As
the formation of a fusion pore by R5 HIV-1 likely requires the
engagement of several CCR5molecules (about 4 to 6) (Kuhmann et al.,
2000; Sougrat et al., 2007), we hypothesize that a greater proportion
of occupied CCR5 molecules may prevent effective engagement of
sufﬁcient CCR5s by sensitive or MVC-resistant viruses. Because MVC-
resistant viruses require higher coreceptor densities when using the
MVC-bound form (Fig. 1) (Heredia et al., 2008; Pugach et al., 2009), an
increase in antibody-bound CCR5 molecules could further prevent
fusion pore formation.
Another possible interpretation is that the HGS mAbs disrupt
conformational changes in CCR5 required for viral entry, especially bye CCR5 on CD4+ T cells. 10-day IL-2 stimulated PBMCs (1×106) were treated with and
ained with the corresponding secondary detection antibody. Lymphocyte subsets were
detection in the CD4+ T cell subset was analyzed by comparing percentages of CCR5
pulations (lower panels). Representative data from two different donors are shown.
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antagonists often become more dependent on interactions with the
N-terminal region (Berro et al., 2009; Laakso et al., 2007; Lin et al.,
2007; Nolan et al., 2009; Pfaff et al., 2010), with the ECL2 region
(Sterjovski et al., 2010), or with both the N-terminal and ECL2 regions
of CCR5 (Agrawal-Gamse et al., 2009; Ogert et al., 2010; Tilton et al.,
2010). We are currently investigating the dependence of MVC
resistant viruses upon the N-terminal and ECL2 regions.
In summary, HGS004 and HGS101, but not the other mAbs tested,
were more potent against MVCres HIV-1 in the presence than in the
absence of MVC and restored MVC inhibition of resistant HIV-1 in
PBMCs. In addition, both HGS004 and HGS101 enhanced MVC
inhibition of MVCsens HIV-1. In a monotherapy clinical trial of
HGS004, treatment was safe but HIV-1 RNA was reduced by N1 log10
in only 54% of patients (Lalezari et al., 2008). Retrospectively, it was
found that sensitivity of the patients' viruses to HGS004 predicted
antiviral responses (Lalezari et al., 2008). Although HGS004 is
currently in clinical development for treating autoimmune disorders,
our results suggest that combinations of MVC and HGS004 could
potentially enhance antiviral responses and control MVC-resistant
viruses in patients with R5 HIV-1. Even better antiviral responses
might be achieved by combining MVC and HGS101, a more potent,
second-generation derivative of HGS004.
Methods
Cell lines, antibodies and inhibitors
293 T cells were cultured in DMEM supplemented with 10% FBS,
100 μg/ml of penicillin and streptomycin, and 0.5 mg/ml of geneticin.
JC-6, -10, -20, -57 and -53 cells, derived from HeLa cells and stably
expressing CD4 and different CCR5 densities (Platt et al., 1998), were
cultured in DMEM supplemented with 10% FBS plus 100 μg/ml
penicillin/streptomycin. Maraviroc and T20 were obtained through
the NIH AIDS Research and Reference Reagent Program (German-
town, MD). CD4 mAb Q4120 was obtained through the National
Institute for Biological Standards and Control (NIBSC, Potters Bar, UK)
(Healey et al., 1990). CCR5 antibodies 2D7 and 45523 were purchased
from BD Biosciences (San Jose, CA) and R&D Systems (Minneapolis,
MN), respectively. CCR5 mAb ROAb14 was a gift from Roche (Palo
Alto, CA), and HGS004 and HGS101 were gifts from Human Genome
Sciences (Rockville, MD).
Single-cycle HIV-1 entry assay
Replication-defective HIV-1 reporter viruses were produced from
2×106 293 T cells transfected with 10 μg of pNL4.3-env−-luc3 and
10 μg of pCI-Env-expressing plasmid (MVCsens or MVCres HIV-1 Env)
using calcium phosphate. MVCsens andMVCres HIV-1 Envs, described
previously (Westby et al., 2007), correspond to Env genes of primary
isolate CC1/85 passaged in PBMCs in the absence and presence of
MVC. The MVCsens HIV-1 Env sequence has amino acids 316A, 319A
and 323I in V3; whereas MVCres HIV-1 Env contains substitutions
316T, 319A and 323V in V3, which confer resistance to MVC (Westby
et al., 2007). Pseudoviruses were collected 48 h after transfection,
debris removed by centrifugation and ﬁltration through a 0.45 μm
syringe ﬁlter, and virus quantiﬁed by p24 ELISA. For infection, JC cells
were plated in 96 well plates at 8×103 cells/well for 2 days. One hour
before infection cells were left untreated or treated with MVC at the
indicated concentrations. In experiments evaluating infection by
MVC-bound CCR5, cells were pretreated with 10 μM MVC. In some
experiments, after MVC pretreatment, cells were incubated for an
additional hour with varying dilutions of inhibitor (CCR5 mAbs, CD4
mAb Q4120, or T20). Cells were infected by spinoculation at 1200×g
for 1 h at 4 °C using 5 ng p24 (O'Doherty et al., 2000; Platt et al., 2005).
Three days later cells were lysed, luciferase activity measured asrelative luciferase units (RLU) using the Luciferase Assay System
(Promega, Madison, WI), and percentage virus infection calculated as
(RLU with inhibitor)/(RLU without inhibitor)×100. Inhibition data
from replicates were plotted using GraphPad Prism software and EC50
values determined using variable slope non-linear regression analysis.Time of inhibitor addition experiments
Pseudoviruses bearing MVCres or MVCsen HIV-1 Env were
spinoculated onto JC6 cells (10 ng p24/0.2×106 cells) at 1600×g for
1 h at 4 °C. Plates were placed in a 37 °C culture incubator to allow
viral entry to proceed. At transfer to 37 °C (time 0) and at subsequent
time points (10, 20, 30, 40, 60, 90 and 120 min), fully inhibitory
concentrations of 2D7 (50 μg/ml) or T20 (10 μM) were added to
inhibit CCR5-dependent steps or viral fusion, respectively. Plates were
incubated for 3 days, cells lysed and luciferase activity determined.
Relative infectivity values were obtained by dividing luciferase
activity (RLU) from a given time point by the activity obtained at
the last time point (120 min). The infection kinetics data were
analyzed by plotting relative infectivity versus time of addition of
inhibitor, and t½ values calculated by ﬁtting the data to one-phase
exponential association curve using GraphPad Prism.Infection of PBMCs with replication-competent HIV-1
PBMCs activated for three days with PHA (2.5 μg/ml) were infected
with previously described replication-competent chimeric viruses
carrying the MVCsens and MVCres Env genes of HIV-1 CC1/85 in a
NL4−3 backbone (Westby et al., 2007). In some experiments, CD8 T cells
were depleted with Dynal magnetic beads (Invitrogen, Carslbad, CA).
Prior to infection, cellswere incubatedwith andwithout 10 μMMVC for
1 h and, in some experiments, followed by 1 h incubation with CCR5
antibodies. Cells were infected using a multiplicity of infection (MOI) of
0.001, washed and cultured in medium containing IL-2 (100 U/ml) and
inhibitors. On day 3, half of the medium was replaced with fresh
medium containing inhibitors at the same concentrations as before.
Virus replicationwasevaluated bymeasuringp24 levels in supernatants
on day 7 and EC50 values determined.Measurement of CCR5 by ﬂow cytometry analysis
PBMCs were cultured for 10 days in complete RPMI culture
medium supplemented with 100 U/ml rhIL-2 (Roche, Indianapolis,
IN) to upregulate CCR5 expression (Bleul et al., 1997). CCR5 staining
was done basically as described (Lalezari et al., 2008; Olson et al.,
1999; Wu et al., 1997). Brieﬂy, cells were washed with PBS, incubated
with FACS staining buffer (PBS, 10% horse serum, 2% human serum,
and 0.01% sodium azide), followed by incubation with saturating
concentrations of unconjugated 2D7, HGS004 or HGS101 (10 μg/106
cells, as determined in saturation binding optimization experiments).
Non-speciﬁc binding was detected with 5 μg of mouse IgG2a (Sigma,
Saint Louis, MO) for 2D7, and with 5 μg of human IgG4 (Sigma, Saint
Louis, MO) for HGS004 or HGS101. 2D7 staining was detected with
phycoerythrin (PE)-labeled rat anti-mouse IgG2a (Becton Dickinson,
San Jose, CA), while HGS004 and HGS101 were detected with PE-
labeled mouse anti-human IgG4 (SouthernBiotech, Birmingham, AL).
Lymphocyte subsets were detected using combinations of ﬂuoro-
chrome labeled antibodies directed to CD3, CD4 and CD8 (Becton
Dickinson). All incubation steps were done at room temperature for
30 min. Data were collected in a Becton Dickinson FACSCalibur ﬂow
cytometer using CellQuest software and analyzed by FlowJo (TreeStar,
Ashland, OR).
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2010.12.029.
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